Improvements have been made to the second phase of an EU pilot that allows drug sponsors to obtain simultaneous scientific advice from two member states.
EU regulators have launched an “optimized” version of their popular pilot program that allows drug developers to seek national scientific advice simultaneously from two EU member states on specific scientific, technical or regulatory issues.
The second phase of the Simultaneous National Scientific Advice (SNSA) pilot incorporates an “an optimised procedure intended to maximise the...
An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.
Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.
EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.
